Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.38 |
| ▸ | CETP | P11597 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30563837 | 0.96 | DGAT1 (0.38) | DGAT1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL20640566 | 0.93 | SMYD2 (0.37) | DGAT1SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4124769 | 0.87 | MMP1 (0.38) | CETPSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL30674892 | 0.85 | SMYD2 (0.35) | DGAT1CETPSMYD2CYP3A4HTT | |
| SCHEMBL30078391 | 0.84 | ABL1 (0.40) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 | |
| SCHEMBL1845926 | 0.81 | SMYD2 (0.42) | CETPSMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL13596143 | 0.80 | SMYD2 (0.36) | SMYD2CYP3A4HTTSMN1; SMN2ADORA3 | |
| SCHEMBL20640525 | 0.79 | OPRM1 (0.43) | CYP2C19SMN1; SMN2 | |
| SCHEMBL4119132 | 0.78 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2ADORA3 | |
| SCHEMBL28887797 | 0.78 | CYP4A11 (0.39) | SMYD2CYP3A4HTTSMN1; SMN2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | DGAT1 2369/4885CETP 3157/4885CYP2C19 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.